Sjögren’s and SOB? Think About ILD! Save
This year’s ACR meeting provided us with a wealth of exciting new developments in the world of Sjögren’s disease (SjD). Our better understanding of SjD pathophysiology has driven therapeutic advancements placing us on the brink of a renaissance period. While we excitedly await FDA approval of novel immunotherapies, it is worth reminding ourselves that the new drugs will be indicated primarily for patients with active systemic manifestations of SjD that is of at least moderate severity based upon a EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) score of ≥5. Of the various systemic domains, pulmonary involvement carries the following weighted scores based on severity [1]:
Low = 5 pts
“Persistent cough due to bronchial involvement with no radiographic abnormalities on radiography Or radiological or HRCT evidence of interstitial lung disease with: no breathlessness and normal lung function test”
Moderate = 10 pts
“Moderately active pulmonary involvement, such as interstitial lung disease shown by HRCT with shortness of breath on exercise (NHYA II) or abnormal lung function tests restricted to: 70% >DLCO ≥40% or 80% >FVC≥60%”
High = 15 pts
“Highly active pulmonary involvement, such as interstitial lung disease shown by HRCT with shortness of breath at rest (NHYA III, IV) or with abnormal lung function tests: DLCO <40% or FVC <60%”
ILD is a particularly worrisome systemic feature of SjD that may be associated with poorer quality of life outcomes and increased mortality. Prevalence of SjD-ILD has been quoted to occur in 10-20% of SjD patients; however, identification of SjD may vary widely based on the testing methodologies used (history, PFTs, imaging) [2]. SjD-ILD encompasses several distinct phenotypes including UIP, NSIP and lymphocytic interstitial pneumonia or LIP which is an ILD classically associated with SjD.
Abstract 0433 was a retrospective single center analysis which studied features of SjD-ILD which provides more data on trends in SjD-ILD. In this Loyal Medical Center SjD population of 373 patients, 70 of them, or about 18%, carried a diagnosis of ILD. UIP (35.7%) was the predominant of the reported patterns followed by NSIP (22.9%) and LIP (8.6%) . The majority of SjD-ILD patients were seropositive for SSA (81.4%). Serologic status for SSB, RF and Ro-52kD were also accounted for. “Triple positive” for SSA, SSB and RF conferred a notably higher association with LIP (OR 15.0, 95% CI 2.26-99.64) [3].
Important points to recognize from this study are:
- The prevalence of ILD here seems to be in agreement with what has been reported in the literature so keep in mind that up to 1 in 5 our SjD patients could have ILD. It is always worth asking about pulmonary symptoms and taking a good listen to lungs, especially the bases (auscultate posterior fields with the patient's arms crossed and leaning slightly forward)
- Serologic status may predict risk for ILD in SjD
- While LIP has long been recognized as a more Sjogren’s specific ILD, both UIP and NSIP are common patterns
References
1.Seror R, Bowman SJ, Brito-Zeron P, et al. EULAR Sjögren’s syndrome disease activity index (ESSDAI): a user guide. RMD Open. 2015;1(1). doi:10.1136/rmdopen-2014-0000222.
2. Highland K, Kreider M. Pulmonary Involvement in Sjögren Syndrome. Seminars in Respiratory and Critical Care Medicine. 2014;35(02):255-264. doi:10.1055/s-0034-13715293.
3. Jayaram S, Ostrowski R, Popescu A, et al. Variation in Pulmonary Complications amongst Primary Sjögren’s Syndrome Patients with Distinct Serological Profiles - ACR Meeting Abstracts. ACR Meeting Abstracts. September 2026. Accessed November 11, 2026. https://acrabstracts.org/abstract/variation-in-pulmonary-complications-amongst-primary-sjogrens-syndrome-patients-with-distinct-serological-profiles/

If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.